Save time and get answers to complex questions with AI chat
Are there specific stretches to avoid while on lipitor?Sun pharma bortezomib?Patent term adjustment semaglutida?Lipitor vs generics what's the price gap?Zemdri nce gain exclusivity 2028 patent 2031?
See the DrugPatentWatch profile for Tyvaso
Tyvaso (treprostinil) is an inhaled formulation of treprostinil, a prostacyclin (PGI2) analog. After inhalation, it helps widen (dilate) pulmonary blood vessels and also inhibits platelet aggregation. In people with pulmonary arterial hypertension, these effects reduce pulmonary vascular resistance, which can improve blood flow through the lungs and lower the pressure load on the heart. [1]
Treprostinil’s main pharmacologic action is prostacyclin receptor (IP receptor) signaling. This leads to smooth muscle relaxation in pulmonary arteries (vasodilation) and helps prevent platelets from clumping (antiplatelet effect). [1]
Because Tyvaso is inhaled, it targets the pulmonary circulation more directly than systemic administration. That design supports local effects in the lungs, aiming to reduce pulmonary arterial pressure and resistance where the disease is centered. [1]
By lowering pulmonary vascular resistance through vasodilation, Tyvaso can help improve symptoms and functional capacity in pulmonary arterial hypertension patients. The drug’s mechanism (pulmonary vasodilation plus antiplatelet activity) is the basis for this overall treatment effect. [1] Sources: [1] FDA. Tyvaso (treprostinil) prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
Other Questions About Tyvaso :